Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized Phase II study of two oral vinorelbine schedules in advanced NSCLC patients unfit for platinum chemotherapy
2014-003859-61Phase 2Completed
- Sponsor
- Pierre Fabre Laboratories
- Start
- Jun 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of vinorelbine in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Pierre Fabre Laboratories. Primary endpoint: Progression Free Survival without Grade 4 toxicity (G4PFS). Started Jun 2015; status: completed.
02
Drugs
vinorelbine
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2014-003859-61.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-003859-61.